Your browser doesn't support javascript.
loading
Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan.
Tsuchihashi, Kenji; Ito, Mamoru; Arita, Shuji; Kusaba, Hitoshi; Kusano, Wataru; Matsumura, Takashi; Kitazono, Takafumi; Ueno, Shohei; Taguchi, Ryosuke; Yoshihiro, Tomoyasu; Doi, Yasuhiro; Arimizu, Kohei; Ohmura, Hirofumi; Kajitani, Tatsuhiro; Nio, Kenta; Nakano, Michitaka; Oshima, Kotoe; Tamura, Shingo; Shirakawa, Tsuyoshi; Shimokawa, Hozumi; Uchino, Keita; Hanamura, Fumiyasu; Okumura, Yuta; Komoda, Masato; Isobe, Taichi; Ariyama, Hiroshi; Esaki, Taito; Hashimoto, Kazuki; Komune, Noritaka; Matsuo, Mioko; Matsumoto, Keiji; Asai, Kaori; Yoshitake, Tadamasa; Yamamoto, Hidetaka; Oda, Yoshinao; Akashi, Koichi; Baba, Eishi.
Affiliation
  • Tsuchihashi K; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Ito M; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Arita S; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Kusaba H; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Kusano W; Department of Medical Oncology Organization, Hamanomachi Hospital, Fukuoka, Japan.
  • Matsumura T; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Kitazono T; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Ueno S; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Taguchi R; Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Yoshihiro T; Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Doi Y; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Arimizu K; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Ohmura H; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Kajitani T; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Nio K; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Nakano M; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Oshima K; Department of Medical Oncology Organization, Hamanomachi Hospital, Fukuoka, Japan.
  • Tamura S; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Shirakawa T; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Shimokawa H; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Uchino K; Department of Medical Oncology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
  • Hanamura F; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Okumura Y; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Komoda M; Department of Hematology and Oncology, Japan Community Health care Organization Kyushu Hospital, Fukuoka, Japan.
  • Isobe T; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Ariyama H; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Esaki T; Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan.
  • Hashimoto K; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Komune N; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Matsuo M; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka, Higashi-ku, 812-8582, Japan.
  • Matsumoto K; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Asai K; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Yoshitake T; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Yamamoto H; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Oda Y; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Akashi K; Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Baba E; Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
BMC Cancer ; 23(1): 1046, 2023 Oct 31.
Article in En | MEDLINE | ID: mdl-37904096
ABSTRACT

BACKGROUND:

Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy.

METHODS:

We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy.

RESULTS:

Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows median age 38 years (range 25 - 63 years), histology (alveolar/spindle) 10/1, and risk group (intermediate/high) 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI 6.0 - 25.8 months) 17.1 months (95%CI 6.0 - not reached (NR)) for patients with stage I-III and 8.5 months (95%CI 5.2 - 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI 12.1 months-NR) 40.8 months (95%CI 12.1 - NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions.

CONCLUSION:

The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rhabdomyosarcoma / Head and Neck Neoplasms Limits: Adult / Humans / Middle aged Country/Region as subject: Asia Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rhabdomyosarcoma / Head and Neck Neoplasms Limits: Adult / Humans / Middle aged Country/Region as subject: Asia Language: En Journal: BMC Cancer Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Japan
...